A Phase 3 interventional study of Lumateperone and Placebos in Bipolar Depression and Major Depressive Disorder, sponsored by Intra-Cellular Therapies, Inc.. Completed at 42 sites in 5 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-03-19.
Sponsored by Intra-Cellular Therapies, Inc. (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies in Bipolar Disorder by Johnson & Johnson — 2 open to participants now, 2 under way, 2 of them phase 3. Bipolar Disorder · Johnson & Johnson.
Among the 39 studies in Bipolar Disorder by Johnson & Johnson, this one is the 7th largest by enrollment of the 36 interventional ones that give a count, is the only one that started in 2020, is one of 28 in phase 3, and was the 34th registered.
1,685 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.
Browse Bipolar Disorder studies →2 of the 39 studies in Bipolar Disorder by Johnson & Johnson are open now, in 4 countries. Recruiting first, the newest first:
Intra-Cellular Therapies, Inc. · Sites in United States, Colombia, India and 1 more country
Ages 10–17
Intra-Cellular Therapies, Inc. · Sites in United States, Colombia, Serbia
Ages 5–17
By country, each count listing its studies:
Of the 208 Bipolar Disorder studies recruiting now, 59 (28%) set no upper age limit and 136 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
First in 1997; this study’s year is marked. 1 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 488 is above the median of 64 across 1,280 interventional studies indexed under Bipolar Disorder.
Median enrollment 300 across the 36 interventional studies, 1,066 across the 3 observational. Of the 37 that completed or were terminated, 9 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Intra-Cellular Therapies, Inc., one of the names counted as Johnson & Johnson. Under that name alone:
Intra-Cellular Therapies, Inc. is the lead sponsor of 41 studies on the registry; 12 are open to participants now.
Of its 24 completed or terminated interventional studies of FDA-regulated products, 11 (46%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 39 studies in Bipolar Disorder by Johnson & Johnson, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of lumateperone monotherapy in the treatment of patients with major depressive episodes associated with Bipolar I or Bipolar II Disorder (Bipolar Depression) or major depressive disorder (MDD) who also meet the Diagnostic and Statistical Manual of Mental Disorder, 5th Edition (DSM-5) criteria for mixed-features. The study consists of a Screening Period, a Double-blind Treatment Period, and a Safety Follow-up Period.
Major Inclusion Criteria:
Major Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Lumateperone 42mg administered once daily in the evening
Drug: Lumateperone
Matching placebo administered once daily in the evening
Drug: Placebos
Lumateperone 42mg oral capsule
Placebo oral capsule
Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score
The Montgomery-Åsberg Depression Rating Scale is a clinician-rated 10 item scale to assess depressive symptoms. Each item is rated on a 7-point scale from 0-6. The total score ranges from 0 to 60 with a higher score indicating increased severity of depressive symptoms.
Time frame: Day 43
Clinical From Baseline in Clinical Global Impression Scale - Severity (CGI-S)
The Clinical Global Impression Scale-Severity is a clinician-rated scale to assess a patient's overall mental health. The scale ranges from 1 (normal, not at all ill) to 7 (among the most extremely ill patients).
Time frame: Day 43
| Milestone | Lumateperone 42mg | Placebo |
|---|---|---|
| Started | 243 | 245 |
| Completed | 211 | 217 |
| Not completed | 32 | 28 |
The Montgomery-Åsberg Depression Rating Scale is a clinician-rated 10 item scale to assess depressive symptoms. Each item is rated on a 7-point scale from 0-6. The total score ranges from 0 to 60 with a higher score indicating increased severity of depressive symptoms.
| score on a scale | Lumateperone 42mg | Placebo |
|---|---|---|
| Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score | -18.1 ± 0.71 | -12.4 ± 0.70 |
The Montgomery-Åsberg Depression Rating Scale is a clinician-rated 10 item scale to assess depressive symptoms. Each item is rated on a 7-point scale from 0-6. The total score ranges from 0 to 60 with a higher score indicating increased severity of depressive symptoms.
| score on a scale | Lumateperone 42mg | Placebo |
|---|---|---|
| Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score | -17.7 ± 1.00 | -12.0 ± 0.96 |
The Montgomery-Åsberg Depression Rating Scale is a clinician-rated 10 item scale to assess depressive symptoms. Each item is rated on a 7-point scale from 0-6. The total score ranges from 0 to 60 with a higher score indicating increased severity of depressive symptoms.
| score on a scale | Lumateperone 42mg | Placebo |
|---|---|---|
| Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score | -18.2 ± 0.95 | -12.2 ± 0.96 |
The Montgomery-Åsberg Depression Rating Scale is a clinician-rated 10 item scale to assess depressive symptoms. Each item is rated on a 7-point scale from 0-6. The total score ranges from 0 to 60 with a higher score indicating increased severity of depressive symptoms.
| score on a scale | Lumateperone 42mg | Placebo |
|---|---|---|
| Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score | -17.7 ± 0.64 | -12.1 ± 0.63 |
The Clinical Global Impression Scale-Severity is a clinician-rated scale to assess a patient's overall mental health. The scale ranges from 1 (normal, not at all ill) to 7 (among the most extremely ill patients).
| score on a scale | Lumateperone 42mg | Placebo |
|---|---|---|
| Clinical From Baseline in Clinical Global Impression Scale - Severity (CGI-S) | -1.8 ± 0.08 | -1.2 ± 0.08 |
The Clinical Global Impression Scale-Severity is a clinician-rated scale to assess a patient's overall mental health. The scale ranges from 1 (normal, not at all ill) to 7 (among the most extremely ill patients).
| score on a scale | Lumateperone 42mg | Placebo |
|---|---|---|
| Clinical From Baseline in Clinical Global Impression Scale - Severity (CGI-S) | -1.8 ± 0.11 | -1.2 ± 0.11 |
The Clinical Global Impression Scale-Severity is a clinician-rated scale to assess a patient's overall mental health. The scale ranges from 1 (normal, not at all ill) to 7 (among the most extremely ill patients).
| score on a scale | Lumateperone 42mg | Placebo |
|---|---|---|
| Clinical From Baseline in Clinical Global Impression Scale - Severity (CGI-S) | -1.7 ± 0.11 | -1.1 ± 0.11 |
The Clinical Global Impression Scale-Severity is a clinician-rated scale to assess a patient's overall mental health. The scale ranges from 1 (normal, not at all ill) to 7 (among the most extremely ill patients).
| score on a scale | Lumateperone 42mg | Placebo |
|---|---|---|
| Clinical From Baseline in Clinical Global Impression Scale - Severity (CGI-S) | -1.7 ± 0.07 | -1.1 ± 0.07 |
Collected over From signing ICF until end of study procedures (~10 weeks), including 6 weeks of double-blind treatment.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lumateperone 42mg | 0/240 (0%) | 0/240 (0%) | 84/240 (35%) |
| Placebo | 0/241 (0%) | 1/241 (0.4%) | 37/241 (15.4%) |
| Event | Lumateperone 42mg | Placebo |
|---|---|---|
| DermatitisSkin and subcutaneous tissue disorders | 0/240 | 1/241 |
| Event | Lumateperone 42mg | Placebo |
|---|---|---|
| HeadacheNervous system disorders | 37/240 | 30/241 |
| SomnolenceNervous system disorders | 31/240 | 4/241 |
| DizzinessNervous system disorders | 28/240 | 4/241 |
| NauseaGastrointestinal disorders | 19/240 | 5/241 |
| Age, Continuous(years) | Lumateperone 42mg | Placebo | Total |
|---|---|---|---|
| Mean | 42.9 ± 14.54 | 43.4 ± 13.89 | 43.2 ± 14.21 |
| Sex: Female, Male(Participants) | Lumateperone 42mg | Placebo | Total |
|---|---|---|---|
| Female | 150 | 148 | 298 |
| Male | 90 | 93 | 183 |
| Race/Ethnicity, Customized(Participants) | Lumateperone 42mg | Placebo | Total |
|---|---|---|---|
| Race — White | 205 | 188 | 393 |
| Race — Black or African American | 32 | 49 | 81 |
| Race — Asian | 1 | 2 | 3 |
| Race — Other | 2 | 1 | 3 |
| Race — Multiple | 0 | 1 | 1 |
| Region of Enrollment(participants) | Lumateperone 42mg | Placebo | Total |
|---|---|---|---|
| United States | 82 | 78 | 160 |
| Ukraine | 20 | 17 | 37 |
| Bulgaria | 75 | 92 | 167 |
| Serbia | 15 | 24 | 39 |
| Russia | 48 | 30 | 78 |
| Montgomery-Asberg Depression Rating Scale(units on a scale) | Lumateperone 42mg | Placebo | Total |
|---|---|---|---|
| Combined MDD and Bipolar Depression Mixed Features Population | 31.3 ± 4.05 | 31.1 ± 4.07 | 31.3 ± 4.06 |
| Bipolar Depression Mixed Features Population | 31.8 ± 4.40 | 31.1 ± 4.01 | 31.5 ± 4.22 |
| MDD Mixed Features Population | 30.8 ± 3.59 | 31.2 ± 4.16 | 31.0 ± 3.88 |
| Overall Population | 31.3 ± 4.33 | 31.4 ± 4.36 | 31.3 ± 4.34 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2020 to primary completion in Nov 2022, 33 months.
Results were first posted in Mar 2025, 2 years 3 months after primary completion.
Of 29 industry-sponsored phase 3 interventional studies under Bipolar Disorder, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 49. This study's 33 months is close to that.
Counting every sponsor, half of 43 studies reached it within 37 months; a quarter within 21 and three quarters within 60.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lumateperone
Intra-Cellular Therapies, Inc. →